Trials / Completed
CompletedNCT00109512
Endometriosis Trial: Study of NBI-56418 in Endometriosis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of NBI-56418 in Endometriosis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 76 (actual)
- Sponsor
- Abbott · Industry
- Sex
- Female
- Age
- 18 Years – 49 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study with subjects randomized to one of three treatment groups, placebo, 75 mg and 150 mg in a 1:1:1 ratio. Study drug was administered once daily for 12 weeks. After the last dose at the end of Week 12, follow-up continued every 4 weeks for 12 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NBI-56418 (GnRH antagonist) | |
| DRUG | placebo |
Timeline
- Start date
- 2005-04-01
- Primary completion
- 2006-06-01
- Completion
- 2006-06-01
- First posted
- 2005-04-29
- Last updated
- 2012-02-22
Locations
15 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00109512. Inclusion in this directory is not an endorsement.